Novo Nordisk has announced significant price reductions for its weight-loss drugs, Wegovy and Ozempic, lowering the cash price to as low as $199 per month. This move aims to increase accessibility for patients amidst ongoing affordability challenges highlighted by healthcare professionals. The recent adjustments include a notable 30% price cut for Wegovy, with plans to match Eli Lilly’s pricing for competing drugs. Despite these reductions, doctors continue to express concerns regarding the overall affordability and financial burden on patients. Additionally, Novo Nordisk has introduced new self-pay offers and further strategies to remain competitive in the weight-loss drug market, particularly in the face of increasing competition from Eli Lilly and others. The changes reflect a broader trend in the pharmaceutical industry to make vital medications more attainable for consumers.